Otsuka (OTCMKTS:OTSKY) Shares Gap Down – Should You Sell?

Otsuka Holdings Co., Ltd. – Unsponsored ADR (OTCMKTS:OTSKY – Get Free Report)’s share price gapped down prior to trading on Monday. The stock had previously closed at $36.92, but opened at $34.99. Otsuka shares last traded at $35.9840, with a volume of 449 shares changing hands.

Analyst Upgrades and Downgrades

Separately, Zacks Research upgraded shares of Otsuka from a “hold” rating to a “strong-buy” rating in a research report on Friday, October 9th. One research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy”.

Get Otsuka alerts:

Read Our Latest Analysis on OTSKY

Otsuka Trading Up 1.9%

The firm has a market cap of $39.53 billion, a price-to-earnings ratio of 14.51, a price-to-earnings-growth ratio of 2.59 and a beta of 0.09. The company has a quick ratio of 1.65, a current ratio of 2.21 and a debt-to-equity ratio of 0.05. The business has a 50 day moving average of $37.35 and a 200 day moving average of $35.54.

Otsuka (OTCMKTS:OTSKY – Get Free Report) last announced its earnings results on Friday, July 31st. The company reported $0.70 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.51 by $0.19. The firm had revenue of $4.41 billion for the quarter, compared to analyst estimates of $3.95 billion. Otsuka had a net margin of 15.50% and a return on equity of 12.86%. Otsuka has set its FY 2026 guidance at 2.119-2.119 EPS. On average, research analysts forecast that Otsuka Holdings Co., Ltd. – Unsponsored ADR will post 2.23 earnings per share for the current fiscal year.

About Otsuka

(Get Free Report)

Otsuka Holdings Co, Ltd. is a Japan-based healthcare company that oversees the Otsuka Group’s pharmaceutical, nutraceutical and consumer health businesses. The company’s operations are primarily conducted through subsidiaries, including Otsuka Pharmaceutical Co, Ltd., which researches, develops, manufactures and markets prescription medicines, over-the-counter products and health-related foods.

Otsuka’s pharmaceutical activities focus on areas such as psychiatry, oncology, cardiovascular and renal medicine, and several other specialized therapeutic fields.

Further Reading

• Five stocks we like better than Otsuka
• A Chinese Rival Just Spooked Memory Stocks—How Worried Should Micron Investors Be?
• Could T-Mobile’s Satellite Competition Fears Create a Buying Opportunity?
• Surgical Precision, Sustainable Returns: Johnson & Johnson Secures Its Cash Flow Runway
• Tesla’s Robotaxi Lands in Paris—But Europe’s Real Fight Is Over Cheap EVs

Receive News & Ratings for Otsuka Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Otsuka and related companies with MarketBeat.com's FREE daily email newsletter.